drugset / Trial / NCT00004187

Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT00004187 ↗

Phase 1/2 Completed Swiss Cancer Institute
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining capecitabine and oxaliplatin in treating patients who have advanced or metastatic colorectal cancer that cannot be surgically removed.

Timeline

Start
1999-06
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1250 mg/m2 Oral
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications